SG Americas Securities LLC acquired a new stake in shares of Denali Therapeutics Inc (NASDAQ:DNLI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,975 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc lifted its position in shares of Denali Therapeutics by 16.3% in the 4th quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock worth $179,000 after buying an additional 1,212 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Denali Therapeutics by 13.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,436 shares of the company’s stock worth $216,000 after buying an additional 1,237 shares during the last quarter. Quantamental Technologies LLC bought a new position in shares of Denali Therapeutics in the 4th quarter worth about $41,000. Essex Investment Management Co. LLC bought a new position in shares of Denali Therapeutics in the 4th quarter worth about $182,000. Finally, Amundi Pioneer Asset Management Inc. bought a new position in shares of Denali Therapeutics in the 4th quarter worth about $194,000. Hedge funds and other institutional investors own 71.69% of the company’s stock.

A number of research firms have recently issued reports on DNLI. Zacks Investment Research upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Wednesday, March 27th. ValuEngine downgraded shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 28th.

In related news, insider Ryan J. Watts sold 18,333 shares of Denali Therapeutics stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $25.03, for a total value of $458,874.99. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $22.05, for a total transaction of $165,375.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,667 shares of company stock worth $1,872,543. Insiders own 21.20% of the company’s stock.

Denali Therapeutics stock opened at $19.09 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.55 and a current ratio of 11.55. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $28.86. The stock has a market capitalization of $1.82 billion, a PE ratio of -48.95 and a beta of 2.28.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $12.88 million. On average, research analysts expect that Denali Therapeutics Inc will post -1.48 earnings per share for the current year.

WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2019/06/04/sg-americas-securities-llc-acquires-new-position-in-denali-therapeutics-inc-dnli.html.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Recommended Story: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc (NASDAQ:DNLI).

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.